|Base Year Market Size
|USD 28.19 Billion
|Forecast Year Market Size
|USD 79.50 Billion
|Fastest Growing Market
The global proteomics market size was valued at USD 28.19 billion in 2022. It is estimated to reach USD 79.50 billion by 2031, growing at a CAGR of 12.21% during the forecast period (2023–2031). The surge in pharmaceutical and biotechnology companies and research organizations specializing in R&D initiatives to identify new proteomics applications, develop new drugs, and enable proteomic biomarker discovery in different chronic diseases is a major market growth driver.
Proteomics is the large-scale study of proteomes, their structure, and their physiological functions. Proteomics is a multidisciplinary field that has significantly benefited from the genetic data generated by various genome projects, including the Human Genome Project. Mark Wilkins coined proteome in 1994 to refer to the entire set of proteins synthesized within a living organism, which are translated from the genome. It incorporates the modifications and alterations occurring to an existing protein when exposed to different conditions.
Proteomics employs diverse technologies for quantifying and identifying proteins, as well as the detection of diagnostic markers, the comprehension of pathogens in cells, and interpreting protein pathways in various diseases. In addition to evaluating the rate of protein synthesis and protein interaction patterns, proteomics has broad applications in drug discovery and the formulation of personalized medications.
Proteomics has enabled the development of new therapies and diagnostic tests for various diseases, especially cancer and rare genetic diseases. The proteomics-based approach is focused on proteins specific to cancerous cells and targets them explicitly. In addition, drugs can be explicitly designed per patients' needs. The surge in the target population worldwide and their unmet medical needs are expected to drive the demand for proteomics solutions.
Thousands of genetic disorders with defined clinical symptoms have been identified worldwide. Likewise, genetic defects have been identified as a major cause of pregnancy loss in developed nations, and almost half of all spontaneous abortions involve a chromosomally abnormal fetus. Cancer has emerged as one of the most common genetic diseases and a leading cause of mortality worldwide. In 2020, cancer contributed to approximately 10 million deaths worldwide. All the factors above drive market growth.
Proteomics is a rapidly growing field of research that is gaining prominence worldwide. For instance, it is widely applied to studying proteins involved in carcinogenesis and discovering biomarkers for clinical use. The surge in research activities in proteomics has resulted in a rise in revenues for several companies.
For instance, on July 29, 2020, Small Business Innovation Research (SBIR), a center within the National Cancer Institute (NCI), announced its plans to fund a project titled "Development of proteomics technologies for the untargeted discovery of the proteome in a typical single cell." The project is dedicated to advancing the research on cancer development and progression. Several R&D initiatives are also implemented through proteomics platforms in many infectious disease diagnostics segments. Thus, the surge in R&D programs in the proteomics field will result in the development of simpler, effective, and accurate proteomics-based tests, boosting market growth.
The high demand for proteomic instruments and software in proteomics research has implicitly accelerated the demand for skilled professionals to operate instruments, software, and samples in many clinical and medical laboratories. In 2018, the American Society for Clinical Laboratory Science (ASCLS) noted a workforce shortage.
The introduction of advanced technologies like AI in diagnostics, machine learning-based automation, and highly automated processes in laboratories is discouraging freshers from applying for laboratory technician roles, limiting the availability of skilled professionals in the market. Due to a lack of funds, many research laboratories perform procedures using conventional methods, which are time-consuming and often produce inaccurate results. Therefore, the shortage of skilled professionals will be a major limitation for the global proteomics market.
In recent years, different proteomics techniques have been applied in diabetes research. With the rapid surge in the incidence of type-2 diabetes worldwide, there has been a heightened interest in mechanisms that trigger the development of these conditions. The advances in proteomic approaches during the last decade have identified high-risk patient populations and greatly enhanced current therapies. The high prevalence of other microvascular complications, such as diabetic nephropathy (DN), has made it imperative for vendors to develop and launch robust early diagnostic and prognostic markers.
For instance, Proteomics International Laboratories' PromarkerD is the world's first proteomics-derived test to predict CKD in patients with type-2 diabetes. The test measures the concentration of protein biomarkers. As per the International Diabetes Federation (IDF), in 2019, the global diabetic population was recorded at 463 million. Therefore, the surge in the prevalence of diabetes is expected to provide tremendous growth opportunities for vendors in the global proteomics market.
Based on region, the global proteomics market is bifurcated into North America, Europe, Asia-Pacific, Latin America, and the Middle East and Africa.
North America is the most significant global proteomics market shareholder and is estimated to grow at a CAGR of 11.70% over the forecast period. Factors such as the surge in the adoption of personalized medicine due to the rise in chronic diseases like cardiovascular diseases and the high mortality rate associated with genetic diseases such as cancer are expected to drive market growth. The region also has highly advanced proteomics laboratories and research centers conducting large-scale research projects per the market demand. These research laboratories collaborate with pharma and biotech companies worldwide. In addition, private and research organizations' high focus on developing proteomics methods based on spectrometry is expected to be a tremendous growth opportunity for the North American proteomics market. The rise in the number of funding initiatives for R&D activities by several regional governments is also expected to offer exponential growth opportunities for key participants in the market during the forecast period.
Europe is expected to exhibit a CAGR of 12.75% over the forecast period. The demand for personalized medicine has increased considerably across Europe in recent years. Many prominent players are focusing on developing personalized medicine using the proteomics approach. The surge in drug discovery and development investments by pharmaceutical and biotechnology companies and research organizations in the region is a primary market growth driver. For instance, in 2019, the European Union awarded EUR 10 million to a consortium of 18 European research groups in mass spectrometry-based proteomics.
Additionally, the surge in research funding and ongoing projects by research institutes and many players in Europe is expected to drive the demand for proteomics solutions, especially in the UK. For instance, in December 2020, UK Biobank, a long-term biobank study in the UK, collaborated with the Biopharma Consortium, which includes ten biopharmaceutical companies, for a pharma proteomics project. The project aims to better understand the disease process for innovative drug development.
The Asia-Pacific proteomics market is expected to witness high growth due to a considerable increase in demand for personalized medicine, the surge in R&D expenditure, the rise in government funding for proteomics, and technological advances. Countries like China, South Korea, Japan, Australia, and India are major revenue contributors to the Asia-Pacific proteomics market. Since the early 2000s, various countries in Asia have emerged as strong players in R&D for various proteomic and genomic projects. Several global vendors are attracted to the Asian market due to their large population. Furthermore, the industrial aspects of proteomics have received a lot of attention in China, Japan, and Korea, resulting in several start-up companies and a positive investment environment within the field of proteomic research at both governmental and private levels. The surge in government and private investments, the establishment of accelerated approval pathways, and the rising elderly population are also boosting the market growth in the region.
In Latin America, several government initiatives are accelerating the market growth. For instance, the Brazilian government has implemented numerous initiatives to increase the adoption of precision medicine. The Brazilian Initiative on Precision Medicine (BIPMed) is an initiative of five Research Innovation and Dissemination Centers (RIDCs). BIPMed is playing a crucial role in the development of precision medicine, which requires advanced technology in proteomics.
In addition, the Mexican Proteomics Society (SMP), a nonprofit association, is engaged in developing proteomics research in Mexico. Therefore, the rise in the popularity of personalized medicine and the surge in research on biomarkers and drug discovery are expected to expedite market growth. However, the lack of skilled professionals, proper R&D infrastructure, government funds, and limited access to proteomes will limit the market growth during the forecast period.
|Agilent Technologies Bio-Rad Laboratories Thermo-Fisher Scientific Danaher Shimadzu Scientific Instruments DiaSorin Bruker HORIBA Illumina INOVIQ LI-COR Biosciences Nautilus Biotechnology Proteome Factory PerkinElmer
|U.K. Germany France Spain Italy Russia Nordic Benelux Rest of Europe
|China Korea Japan India Australia Taiwan South East Asia Rest of Asia-Pacific
|Middle East and Africa
|UAE Turkey Saudi Arabia South Africa Egypt Nigeria Rest of MEA
|Brazil Mexico Argentina Chile Colombia Rest of LATAM
|Revenue Forecast, Competitive Landscape, Growth Factors, Environment & Regulatory Landscape and Trends
We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports
The global proteomics market is bifurcated into products, applications, and end-users.
Based on product, the global market is segmented into instruments and software, consumables and reagents, and services.
The consumables and reagents segment is the highest contributor to the market and is projected to grow at a CAGR of 11.83% throughout the forecast period. Proteomics researchers require high-quality reagents and consumables to carry out research. Sample preparation is an essential component of proteomics research. Buffers, detergents, enzymes, and kits are major reagents used in the sample preparation/extraction part of proteomics research. In addition, several small and large established companies offer a wide range of reagents used in sample preparation steps of microarray, spectrometry, chromatography, electrophoresis, immunoassay, and protein fractionation studies.
Proteomics services are largely applied to analyze a single protein or used for the large-scale analysis of a specific proteome, including protein abundances, protein-protein interaction, protein modifications, and protein-compound interactions. Some companies offer services for proteomic applications and proteomic analysis in their facilities for a comprehensive range of customers, including pharmaceutical companies and research organizations. Some standalone service providers offer services, while others provide products and services for proteomics research.
Based on application, the global market is segmented into drug discovery and development and translational research, clinical applications, and forensics and applied proteomics.
The drug discovery and development and translational research segment is the largest revenue contributor to the market and is expected to exhibit a CAGR of 11.57% over the forecast period. Proteomics is supporting researchers in several stages of drug discovery and development processes. These processes include analyzing novel targets, understanding disease mechanisms and structure-based drug design, and discovering the mode of action of lead compounds. In addition, proteomic methodologies have proven valuable tools to provide novel insights into disease progression. Proteomic analysis can provide insights into the peptide sequence and the quantification of protein abundance, post-translational modifications (PRMs), and protein interactions. Considering the complexity of the proteome, interpreting proteomics data is certainly more challenging. Thus, proteomics has demonstrated tremendous potential in drug discovery and development.
Proteomics in clinical applications aims to identify proteins involved in pathological processes, understand how changes in protein expression cause illnesses, develop biomarkers to improve diagnosis and provide personalized therapeutics. With advances in MS and other advanced analytical techniques, proteomics workflows enable the profiling of large datasets with high precision and resolution required for biomarker discovery. Several reliable and validated methods have been developed for protein separation and analysis, key processes for identifying protein biomarkers. Other useful tools for protein separation include capillary electrophoresis and affinity chromatography.
Based on end-users, the global market is bifurcated into pharmaceutical and biotechnology companies, academic and research institutes, hospitals, and diagnostic and forensic laboratories.
The pharmaceutical and biotechnology company segment dominates the global market and is predicted to exhibit a CAGR of 11.94% during the forecast period. Several biotechnology and pharmaceutical firms are extensively using proteomics technologies in their R&D facilities to develop proteomics-based reagents and instruments, protein-based kits for diagnosis and therapeutics, and the discovery of novel targets. The importance of proteomics in the pharmaceutical industry has increased in recent years. The rise in focus on biomarker discovery, drug discovery and development, and personalized medicine has compelled pharmaceutical and biotechnology companies to focus on extensive research and launch advanced solutions. Such initiatives will be a major revenue generator in the global proteomics market.
The global proteomics market is witnessing exponential growth, with academic and research institutes focusing on proteomics research studies and developing in-house proteomics facilities. Their research is mostly focused on biomarker discovery and drug discovery and development in the areas of cancer and many other chronic diseases. Many academic and research facilities have adopted advanced proteomics technologies to advance their research studies, propelled by the surge in government funding.